Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

CorMedix (CRMD) Operating Expenses (2016 - 2025)

CorMedix (CRMD) has disclosed Operating Expenses for 13 consecutive years, with $48.2 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 181.79% to $48.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $125.6 million through Dec 2025, up 100.53% year-over-year, with the annual reading at $125.6 million for FY2025, 100.53% up from the prior year.
  • Operating Expenses hit $48.2 million in Q4 2025 for CorMedix, up from $41.7 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $48.2 million in Q4 2025 to a low of $5.9 million in Q2 2021.
  • Historically, Operating Expenses has averaged $14.8 million across 5 years, with a median of $11.0 million in 2023.
  • Biggest five-year swings in Operating Expenses: crashed 34.11% in 2021 and later skyrocketed 196.9% in 2025.
  • Year by year, Operating Expenses stood at $7.8 million in 2021, then increased by 8.09% to $8.4 million in 2022, then rose by 24.34% to $10.5 million in 2023, then soared by 63.35% to $17.1 million in 2024, then surged by 181.79% to $48.2 million in 2025.
  • Business Quant data shows Operating Expenses for CRMD at $48.2 million in Q4 2025, $41.7 million in Q3 2025, and $18.3 million in Q2 2025.